GlassScriptPhysician profile
Matthew Griffin Mcintyre
NPI 1659450666
$6,060.97
in general payments reported to CMS, 2019-2025
36 companies · $3,198 in 2025
The $3,198 reported for 2025 was more than what 87% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $273 · 2021: $639 · 2022: $520 · 2023: $497 · 2024: $380 · 2025: $3,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,104 · Food and Beverage: $1,922 · Education: $48.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,104.00 |
| Food and Beverage | $1,922.18 |
| Education | $48.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Urology Network, LLC | $2,660.00 | 2025 | |
| Astellas Pharma US INC | $542.79 | 2019-2023 | Xtandi |
| Boston Scientific Corporation | $302.55 | 2019-2025 | Lithoclast, Axonics |
| Janssen Biotech, INC. | $269.22 | 2019-2025 | Erleada |
| Pfizer INC. | $248.90 | 2019-2023 | |
| Medtronic, INC. | $215.23 | 2023-2024 | Interstim |
| Dendreon Pharmaceuticals LLC | $214.73 | 2019-2025 | Provenge |
| Urogen Pharma, INC. | $214.05 | 2022-2025 | Jelmyto |
| Sumitomo Pharma America, INC. | $159.21 | 2023-2025 | Orgovyx, Gemtesa |
| Depuy Synthes Sales INC. | $126.40 | 2025 | Trufill |
| Procept Biorobotics Corporation | $93.12 | 2024 | Aquabeam System |
| Axonics, INC. | $90.20 | 2023 | Axonics, Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $84.25 | 2021-2024 | |
| Coloplast Corp | $81.62 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $79.39 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $74.70 | 2021-2022 | |
| Allergan, INC. | $71.72 | 2020-2021 | |
| Antares Pharma, INC. | $59.97 | 2019 | |
| Blue Earth Diagnostics | $55.99 | 2019 | |
| Intuitive Surgical, INC. | $52.22 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $49.95 | 2019-2020 | |
| Baxter Healthcare | $35.80 | 2019-2021 | |
| Accord Healthcare, INC. | $34.05 | 2023-2024 | |
| Neotract INC. | $28.89 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.69 | 2023 | |
| Olympus America INC. | $24.40 | 2023 | Itind System |
| Endo USA, INC. | $23.59 | 2024 | Aveed, Xiaflex |
| Innovation Technologies INC | $23.11 | 2025 | Irrisept |
| Photocure INC | $22.44 | 2019 | |
| Rochester Medical Corporation | $16.00 | 2019 | |
| Mission Pharmacal Company | $14.44 | 2022 | |
| Myriad Genetic Laboratories, INC. | $13.76 | 2022 | |
| Verity Pharmaceuticals INC. | $13.54 | 2025 | Trelstar |
| Abbvie INC. | $13.20 | 2023 | |
| Halozyme INC | $12.87 | 2023 | |
| Teleflex LLC | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$41,300.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mcintyre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.